TIDMAPH

RNS Number : 6758N

Alliance Pharma PLC

28 October 2016

 
 For immediate release                    28 October 2016

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Appointment of Deputy CEO

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that in addition to his role as Chief Commercial Officer, Peter Butterfield, an executive Director of the Company, is appointed Deputy CEO with immediate effect.

Peter joined Alliance's Board in February 2010 when he transferred to Alliance as part of the Company's acquisition of Cambridge Laboratories.

John Dawson, Alliance Pharma's Chief Executive, said: "Over the past six years it has been a pleasure working alongside Peter. He has made a substantial contribution to the development of the Company and to the senior leadership team. I am delighted with this appointment and I am sure he will excel in this new role as Deputy CEO."

For further information:

 
 Alliance Pharma plc                             + 44 (0) 1249 466966 
 John Dawson, Chief Executive 
  Andrew Franklin, Chief Financial 
  Officer 
 Sarah Robinson, Company Secretary 
 www.alliancepharma.co.uk 
                                                     + 44 (0) 20 7466 
 Buchanan                                                        5000 
 Mark Court / Sophie Cowles 
  / Jane Glover 
 
                                                     + 44 (0) 20 7260 
 Numis Securities Limited                                        1000 
 Nominated Adviser: Michael 
  Meade / Freddie Barnfield 
 Corporate Broking: James 
  Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFLDIILDFIR

(END) Dow Jones Newswires

October 28, 2016 02:00 ET (06:00 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Alliance Pharma Charts.